Janssen Considers Closing Swiss Factory, Affecting Hundreds

A major pharmaceutical company is considering closing its factory in Berne-Bümpliz, Switzerland, potentially impacting up to 300 employees. The parent company, Johnson & Johnson, initiated consultations with employees on Tuesday to explore alternatives.

Factors Behind the Possible Closure

The potential closure of the Bern plant is influenced by two main factors, according to Johnson & Johnson. A new vaccine designed to prevent infections caused by Colibacilli did not achieve the expected effectiveness. Furthermore, the production of lentiviral vectors will soon cease in Bern.

This move aligns with the parent company’s plans to open a significantly larger factory in the Netherlands, as stated in a recent announcement.

“We are committed to supporting our employees during this transition and exploring all possible options,”

—Spokesperson, Johnson & Johnson

According to the World Health Organization, the pharmaceutical industry in Switzerland is a significant contributor to the economy, with over 300 companies employing nearly 40,000 people (WHO 2024).

A Historical Perspective

The factory in Bern, which houses Janssen’s activities, has a rich history. It was established in 1898 under the name of the Swiss serotherapeutic and vaccine institute.